cedar pollinosis
Conditions
Interventions
investigational material(s)
Generic name etc : Nasonex
INN of investigational material : mometasone furoate nasal spray: MFNS
Therapeutic category code : 132 Agents for otic and nasal use
Dosage and A
Sponsors
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The age ranged from 18 to 64 years and subjects met the following inclusion criteria: a positive allergen-specific skin test (wheal diameter: 10mm or >10mm) to a standardized cedar pollen extract (Torii Pharmaceutical Co. Ltd., Tokyo, Japan) and serum cedar pollen-specific immunoglobulin (Ig) E level score of 2 or >2 by the CAP radioallergosorbent test (CAP-RAST; SRL, Tokyo, Japan).
Exclusion criteria
Exclusion criteria: The exclusion criteria included complication of moderate/severe perennial allergic rhinitis which required treated, a history of severe asthma, use of anti-allergic drugs within 4 weeks, and a prior history of any allergen-specific immunotherapy, pregnant women, or women of childbearing potential.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients received nasal steroid or anti-histamine for 7 consecutive days (days 1-7). The main criteria for the evaluation of efficacy was the TNSS for 0-3 hours during the chamber exposure and 3-12 hours after the exposure on day 8. The primary efficacy variables were the mean TNSS for 0-12 hours on day 8 and the mean TNSS of 0-3 hours only in the chamber on day 8. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary efficacy variable included: the number of sneezing and rhinorrhea in the chamber (0-3 hours) and after leaving the chamber (3-12 hours) on day 8 and the mean TNSS on days 9-12. | — |
Outcome results
None listed